Why is Aarey Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with a -18.37% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.28
- The company has been able to generate a Return on Equity (avg) of 3.75% signifying low profitability per unit of shareholders funds
2
Flat results in Sep 26
- NET SALES(Latest six months) At Rs 133.25 cr has Grown at -28.50%
- NON-OPERATING INCOME(Q) is 97.59 % of Profit Before Tax (PBT)
3
Stock is technically in a Bullish range
- The technical trend has improved from Mildly Bullish on 18-Nov-26 and has generated 7.57% returns since then
- Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and OBV
4
With ROCE of 2.2, it has a Fair valuation with a 2.1 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 24.99%, its profits have risen by 26.3% ; the PEG ratio of the company is 6.6
How much should you hold?
- Overall Portfolio exposure to Aarey Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aarey Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Aarey Drugs
24.99%
0.47
53.29%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
-3.08%
EBIT Growth (5y)
-18.37%
EBIT to Interest (avg)
1.28
Debt to EBITDA (avg)
7.16
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
2.81
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.72%
ROCE (avg)
2.55%
ROE (avg)
3.75%
Valuation Key Factors 
Factor
Value
P/E Ratio
82
Industry P/E
19
Price to Book Value
2.46
EV to EBIT
148.22
EV to EBITDA
66.45
EV to Capital Employed
2.10
EV to Sales
1.00
PEG Ratio
6.64
Dividend Yield
NA
ROCE (Latest)
2.17%
ROE (Latest)
3.00%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Bullish
Technical Movement
3What is working for the Company
PAT(9M)
Higher at Rs 3.95 Cr
-3What is not working for the Company
NET SALES(Latest six months)
At Rs 133.25 cr has Grown at -28.50%
NON-OPERATING INCOME(Q)
is 97.59 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Aarey Drugs
Profit After Tax (PAT) - Nine Monthly
At Rs 3.95 cr has Grown at 38.11%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
Higher at Rs 3.95 Cr
than preceding 12 month period ended Sep 2026 of Rs 3.43 crMOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
PAT (Rs Cr)
Here's what is not working for Aarey Drugs
Net Sales - Latest six months
At Rs 133.25 cr has Grown at -28.50%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Non Operating Income - Quarterly
is 97.59 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT